GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds.

[LazysodLondon]

Just saw this in a news feed, the basics are if on a GLP-1 it may cause your scan to highlight areas that may be misinterpreted by the clinicians. At present they do not recommend stopping GLP-1's or making any other changes before these procedures but for the imaging teams to carefully check the medical history of the patient.

Well I know that some are going to say that "they should be doing that anyway!", and yes of course they should but how many people dont have it mentioned on their record that they are taking it? (which will lead to my next post but didnt want to clog this one up).

GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds

Researchers from Alliance Medical Ltd. performed a retrospective case series review of oncologic FDG PET-CT scans in patients taking GLP-1 agonists. They observed several atypical patterns of tracer uptake that could be misinterpreted as pathology if a patient’s medication history is not considered.

www.eurekalert.org

 

[miss-sanne]

If I was going for a PET-CT, which at least in Denmark is only done when looking for cancer, I think, I would tell them. It's quite important. Anyway, I have a Mounjaro prescription on my file, so it's already there.

Thanks for that one, very interesting.